Supplementary materials: Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers

These are peer-reviewed supplementary materials for the article 'Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers' published in the Journal of Comparative Effectiveness Research.Supplementary Figure 1: One-way sensitivity analysis for larotrectinib vs. entrectinib on QALYs gained in colorectal cancerSupplementary Figure 2: One-way sensitivity analysis for larotrectinib vs. entrectinib on QALYs gained in soft tissue sarcomaSupplementary Table 1: Sensitivity analysis fitting an exponential curve through the median points for progression-free and overall survival for entrectinibAim: To extrapolate clinical trial results to estimate and compare expected progression-free and overall life years (LYs) and quality-adjusted LYs (QALYs) for larotrectinib and entrectinib in patientswith colorectal cancer (CRC), soft tissue sarcoma (STS) and brain metastases prior to treatment with larotrectinib or entrectinib. Methods: A naive direct comparison of larotrectinib versus entrectinib was made using partitioned survival modeling methods from clinical trial data. Results: Larotrectinib resulted in an additional 1.58 LYs (1.17 QALYs), 5.81 LYs (2.02 QALYs) and 1.01 LYs in CRC, STS and baseline brain metastases, respectively, compared with entrectinib. Conclusion: Larotrectinib provided life expectancy and QALY gains compared with entrectinib. Additional studies will be beneficial as more patients are treated and survival data develop to better inform comparative effectiveness results.

本数据集为发表于《比较有效性研究杂志》上的文章《拉罗他昔尼与恩曲他昔尼在治疗NTRK基因融合转移性癌症中的比较有效性》的同行评审补充材料。补充图1：拉罗他昔尼与恩曲他昔尼在结直肠癌中获得的质量调整生命年（QALY）的一元敏感性分析；补充图2：拉罗他昔尼与恩曲他昔尼在软组织肉瘤中获得的质量调整生命年（QALY）的一元敏感性分析；补充表1：对恩曲他昔尼的无进展生存期和总生存期的中位数点进行指数曲线拟合的敏感性分析。研究目标：旨在通过外推临床试验结果，估算并比较拉罗他昔尼与恩曲他昔尼在结直肠癌（CRC）、软组织肉瘤（STS）和脑转移患者在接受拉罗他昔尼或恩曲他昔尼治疗前预期的无进展生存年（LYs）和总生存年（LYs）以及质量调整生存年（QALYs）。研究方法：采用临床试验数据，通过分区生存模型方法对拉罗他昔尼与恩曲他昔尼进行了一元直接比较。研究结果：与恩曲他昔尼相比，拉罗他昔尼在CRC、STS和基线脑转移中分别额外增加了1.58年生存年（1.17 QALYs）、5.81年生存年（2.02 QALYs）和1.01年生存年。研究结论：与恩曲他昔尼相比，拉罗他昔尼提供了生存期望和质量调整生存年的增益。随着更多患者的治疗和生存数据的积累，将有益于更全面地了解比较有效性结果。